Page 58 - GPD-4-1

Gene & Protein in Disease GPER1 in brain and heart diseases

deficiency induces cardiac remodeling through oxidative 258. Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation
stress. Transl Res. 2018;199:39-51. and the risk of myocardial infarction. JAMA Intern Med.
2014;174(1):107-114.
doi: 10.1016/j.trsl.2018.04.005
doi: 10.1001/jamainternmed.2013.11912
251. Kander MC, Cui Y, Liu Z. Gender difference in oxidative
stress: A new look at the mechanisms for cardiovascular 259. Chao TF, Huang YC, Liu CJ, et al. Acute myocardial infarction
diseases. J Cell Mol Med. 2017;21(5):1024-1032. in patients with atrial fibrillation with a CHA2DS2-VASc
score of 0 or 1: A nationwide cohort study. Heart Rhythm.
doi: 10.1111/jcmm.13038
2014;11(11):1941-1947.
252. Ide T, Tsutsui H, Ohashi N, et al. Greater oxidative stress in
healthy young men compared with premenopausal women. doi: 10.1016/j.hrthm.2014.08.003
Arterioscler Thromb Vasc Biol. 2002;22(3):438-442. 260. Pierdomenico SD, Coccina F. Atrial cardiopathy and hypertension:
A deadly association. Am J Hypertens. 2023;36(1):14-16.
doi: 10.1161/hq0302.104515
doi: 10.1093/ajh/hpac095
253. Bopassa JC, Eghbali M, Toro L, Stefani E. A novel estrogen
receptor GPER inhibits mitochondria permeability 261. Bagchi RA, Weeks KL. Histone deacetylases in cardiovascular
transition pore opening and protects the heart against and metabolic diseases. J Mol Cell Cardiol. 2019;130:151-159.
ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. doi: 10.1016/j.yjmcc.2019.04.003
2010;298(1):H16-H23.
262. Sawa Y, Matsushita N, Sato S, et al. Chronic HDAC6
doi: 10.1152/ajpheart.00588.2009
activation induces atrial fibrillation through atrial electrical
254. Adu-Amankwaah J, Adekunle AO, Tang Z, et al. Estradiol and structural remodeling in transgenic mice. Int Heart J.
contributes to sex differences in resilience to sepsis-induced 2021;62(3):616-626.
metabolic dysregulation and dysfunction in the heart via doi: 10.1536/ihj.20-703
GPER-1-mediated PPARδ/NLRP3 signaling. Metabolism.
2024;156:155934. 263. Sugishita K, Uchida M, Ikeda M, et al. Gender difference in
subjective symptoms related to paroxysmal atrial fibrillation
doi: 10.1016/j.metabol.2024.155934
is also detected in postmenopausal women. Int Heart J.
255. Sharma M, Bhatt LK. Emerging therapeutic targets for heart 2005;46(4):669-678.
failure. Curr Cardiol Rep. 2022;24(11):1737-1754.
doi: 10.1536/ihj.46.669
doi: 10.1007/s11886-022-01789-z
264. Liu D, Zhan Y, Ono K, et al. Pharmacological activation of
256. Linz D, Gawalko M, Betz K, et al. Atrial fibrillation: estrogenic receptor G protein-coupled receptor 30 attenuates
Epidemiology, screening and digital health. Lancet Reg angiotensin II-induced atrial fibrosis in ovariectomized
Health Europe. 2024;37:100786. mice by modulating TGF-β1/smad pathway. Mol Biol
Rep. 2022;49(7):6341-6355.
doi: 10.1016/j.lanepe.2023.100786
doi: 10.1007/s11033-022-07444-8
257. Gopinathannair R, Chen LY, Chung MK, et al. Managing
atrial fibrillation in patients with heart failure and 265. Baik SH, Baye F, McDonald CJ. Use of menopausal hormone
reduced ejection fraction: A scientific statement from the therapy beyond age 65 years and its effects on women’s
American Heart Association. Circ Arrhythm Electrophysiol. health outcomes by types, routes, and doses. Menopause.
2021;14(6):HAE0000000000000078. 2024;31(5):363-371.
doi: 10.1161/HAE.0000000000000078 doi: 10.1097/GME.0000000000002335

Volume 4 Issue 1 (2025) 29 doi: 10.36922/gpd.4632